BioAffinity Technologies Inc. (BIAF)
NASDAQ (CM) NASDAQ (CM) Primary Summary
BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
bioAffinity and Biodesix pursue different cancer diagnostics strategies, but which oncology stock offers better long-term upside? Let's dive in.
bioAffinity Technologies, Inc. (BIAF) Discusses Innovations in Lung Cancer Screening Technologies for Veterans Transcript
bioAffinity Technologies, Inc. (BIAF) Discusses Innovations in Lung Cancer Screening Technologies for Veterans Transcript
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?
bioAffinity's CyPath Lung sales momentum is gaining traction, but wider losses, funding needs and regulatory risks keep pressure on the stock.
BioAffinity Technologies Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SAS Stephane Astruc/ Salomon Sebban J. Safra Sarasin Holding AG | 42,600 | $164,010 | $29,470.68 | -$134,539.32 | -82.03% |
| KMT Kirk M. Tokheim Ameritas Advisory Services LLC | 1,000 | $3,830 | $688.4 | -$3,141.6 | -82.03% |
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 1 | $4 | $0.7 | -$3.3 | -82.5% |
BioAffinity Technologies Inc. (BIAF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BioAffinity Technologies Inc. ever had a stock split?
BioAffinity Technologies Inc. Profile
| Professional Services Industry | Industrials Sector | Maria Zannes CEO | NASDAQ (CM) Exchange | 09076W307 CUSIP |
| US Country | 57 Employees | - Last Dividend | 19 Sep 2025 Last Split | - IPO Date |
Overview
bioAffinity Technologies, Inc. is an innovative company at the forefront of non-invasive diagnostic development for early-stage lung cancer and other lung diseases. Since its inception in 2014, the company has dedicated itself to advancing healthcare through the early detection of lung diseases, a vital step in improving patient outcomes. Based in San Antonio, Texas, bioAffinity Technologies is committed to offering groundbreaking solutions for the early diagnosis of life-threatening conditions, aiming to significantly impact public health positively.
Products and Services
- CyPath Lung
The flagship product of bioAffinity Technologies, CyPath Lung, represents a significant advancement in the field of lung disease diagnostics. This non-invasive diagnostic test is designed for the early detection of lung cancer, targeting one of the most common and deadliest forms of cancer worldwide. By focusing on early-stage detection, CyPath Lung aims to improve survival rates by enabling earlier and more effective treatment options for patients.
